These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment]. Basset V; Flamand V; Crouzet S; Ploussard G Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738 [TBL] [Abstract][Full Text] [Related]
27. [Treatment sequence using newly developed agents for men with castration resistant prostate cancer]. Fujimoto N Nihon Rinsho; 2014 Dec; 72(12):2193-7. PubMed ID: 25518357 [TBL] [Abstract][Full Text] [Related]
29. Role of BET proteins in castration-resistant prostate cancer. Fernandez-Salas E; Wang S; Chinnaiyan AM Drug Discov Today Technol; 2016 Mar; 19():29-38. PubMed ID: 27769354 [TBL] [Abstract][Full Text] [Related]
30. Cabazitaxel for the treatment of prostate cancer. Michielsen DP; Braeckman JG; Denis L Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025 [TBL] [Abstract][Full Text] [Related]
31. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222 [TBL] [Abstract][Full Text] [Related]
32. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A; Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031 [TBL] [Abstract][Full Text] [Related]
33. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115 [TBL] [Abstract][Full Text] [Related]
34. New drugs in the treatment of elderly patients with metastatic castration-resistance prostate cancer. Genestreti G; Di Battista M; Cavallo G; Brandes AA Tumori; 2016 Aug; 102(4):361-6. PubMed ID: 27151879 [TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Katzenwadel A; Wolf P Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001 [TBL] [Abstract][Full Text] [Related]
37. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
38. Cytotoxic compounds in the treatment of castration-resistant prostate cancer. Lee P; Aragon-Ching JB Anticancer Agents Med Chem; 2009 Dec; 9(10):1040-5. PubMed ID: 19719458 [TBL] [Abstract][Full Text] [Related]
39. A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer. Ryan C; Shore ND; Concepcion R Postgrad Med; 2013 Nov; 125(6):114-6. PubMed ID: 24200767 [TBL] [Abstract][Full Text] [Related]
40. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]